Allergic rhinitis is often dismissed as a nuisance condition, a matter of sneezing and congestion that comes and goes with the seasons. Yet behind those familiar symptoms lies a complex biological event that unfolds simultaneously in two very different places: the inflamed lining of the nose and the circulating bloodstream. Most clinical monitoring, however, looks at only one of these compartments at a time, which means researchers have had an incomplete picture of how allergic disease develops and, crucially, how it resolves during treatment. A new study published in the journal iMetaMed by researchers affiliated with the International Society for Health Data Science set out to close that gap by tracking metabolism in both nasal secretions and plasma at the same time, before and after a full course of allergen immunotherapy.
The study focused on house dust mite allergy, one of the most common and persistent triggers of allergic rhinitis worldwide. The researchers enrolled 28 patients with house dust mite-induced allergic rhinitis who completed six months of subcutaneous immunotherapy, the classic injection-based treatment in which gradually increasing doses of allergen are administered to retrain the immune system. To ensure that the metabolic changes they observed were meaningful, they required that every enrolled patient achieved at least a 50 percent reduction in total visual analogue scale symptom score over the course of treatment. Alongside these patients, the team recruited 19 non-atopic healthy controls to serve as a reference point for the healthy state.
The sampling design was deliberately paired. Plasma and nasal secretion samples were collected from the patients both before and after the six-month immunotherapy course, while the healthy controls provided a single set of samples. In total, the study yielded 150 biospecimens. Each specimen was subjected to untargeted liquid chromatography-mass spectrometry metabolomics, an analytical approach that captures thousands of small molecules without presupposing which ones matter. After rigorous quality control, the dataset retained 831 metabolites in plasma and 989 metabolites in nasal secretions, providing an unusually rich dual-compartment view of allergic biology.
The first major finding was that the disease signal is far broader in the nose than in the blood. Applying a false discovery rate-adjusted threshold to control for the enormous number of statistical comparisons inherent in metabolomics, the team identified 500 nasal secretion metabolites and 208 plasma metabolites associated with allergic rhinitis when compared with healthy controls. In other words, the local mucosal compartment carried more than twice as many disease-associated metabolic features as the systemic circulation. This asymmetry makes intuitive sense, since the nasal mucosa is the direct site of allergen contact and inflammation, but quantifying it so clearly underscores how much information single-compartment monitoring has been missing.
When the researchers turned to the treatment itself, comparing each patient’s samples before and after six months of subcutaneous immunotherapy, they found 98 treatment-responsive metabolites in nasal secretions and 40 in plasma. Notably, neither compartment fully returned to the healthy-control profile after treatment. Recovery, in metabolic terms, was partial. Yet the shift toward the healthy state was more evident in nasal secretions than in plasma, suggesting that the inflamed mucosal barrier responds to immunotherapy with a more pronounced metabolic remodeling than the systemic circulation does over the same six-month window.
Pathway and trajectory analyses then revealed what the researchers describe as a division of labor between the two compartments. The plasma changes were enriched for nucleotide turnover, NAD-plus-related metabolism, and bioenergetic and redox pathways, a pattern consistent with systemic inflammatory and metabolic stress. Nasal secretions, by contrast, showed stronger remodeling of lipid, steroid, and redox-related metabolism, processes tied to the inflamed mucosal barrier and its recovery. When the team arranged the samples along a continuum from healthy control to allergic rhinitis to post-treatment, these patterns coalesced into two coordinated but temporally asynchronous axes: a plasma nucleotide and NAD-plus axis and a nasal lipid-steroid-redox axis. The two compartments, in effect, recover on different schedules and through different metabolic languages.
To make this compartment preference quantitative rather than merely descriptive, the researchers developed a novel metric called the Nasal-Plasma Contrast Index, or NPCI, computed for the 600 metabolites detected in both matrices. By integrating the NPCI with temporal clustering and differential analysis across the disease and treatment states, they prioritized 30 exploratory candidate features as the most informative metabolic signatures in the dataset. Among these, one nasal-enriched feature annotated as ATP stood out. It was significant in both the disease-state comparison and the treatment comparison, and it followed a coherent temporal trajectory across the healthy-allergic-recovery continuum, making it a leading candidate readout for future validation studies.
The team also examined whether any of the metabolic features correlated with the magnitude of symptom improvement each patient experienced. Some response-intensity signals did appear, but none of them remained statistically significant after correction for multiple testing. The authors are careful to frame these associations as hypothesis-generating rather than established findings, a level of caution that reflects the realities of untargeted metabolomics, where relative abundance and putative annotations can easily be overinterpreted without confirmatory assays.
Indeed, the study comes with a set of clearly stated limitations that any reader should keep in mind. It was not designed to establish a clinical response-prediction model. Every enrolled patient improved during immunotherapy, which means the cohort contained no non-responders, no untreated longitudinal controls, and no placebo group, so the metabolic signatures of treatment failure remain unexplored. Untargeted metabolomics also reports relative feature abundance rather than absolute concentrations, and for some metabolites the structural identification remains putative rather than definitive. The authors emphasize that prospective studies including both responders and non-responders, targeted quantitative assays, and independent validation cohorts will be required before any of the 30 candidate features can be considered for clinical use.
Even with those caveats, the conceptual contribution of the work is substantial. By sampling the nose and the blood in parallel, before and after treatment, and against a healthy reference group, the study demonstrates that local and systemic compartments carry complementary, non-redundant information about allergic disease and its resolution. The plasma nucleotide and NAD-plus axis and the nasal lipid-steroid-redox axis together sketch a map of how immunometabolic recovery unfolds during allergen immunotherapy, and the Nasal-Plasma Contrast Index offers a reusable tool for quantifying where any given metabolic signal lives. For a condition affecting hundreds of millions of people, the message is that recovery is not a single process but a coordinated duet between mucosa and circulation, and that listening to both voices may ultimately be the key to understanding who recovers, how quickly, and why.
Subject of Research: Paired nasal and plasma metabolomics of house dust mite allergic rhinitis during subcutaneous immunotherapy
Article Title: Paired nasal and plasma metabolomics reveal distinct recovery trajectories during allergy immunotherapy
Article References: Paired nasal and plasma metabolomics reveal distinct recovery trajectories during allergy immunotherapy. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: allergic rhinitis, metabolomics, subcutaneous immunotherapy, house dust mite allergy, nasal secretions, plasma, NAD metabolism, lipid remodeling, Nasal-Plasma Contrast Index, biomarkers, mucosal immunity, iMetaMed
News Source: Nathaniel Bowman. (October 17, 2026). Nose and Blood Tell Different Recovery Stories in Allergy Immunotherapy Study. Scienmag.
